OMEROS CORP Deferred Revenue, Revenue Recognized (Deprecated 2016-01-31)
OMEROS CORP (OMER) reported Deferred Revenue, Revenue Recognized (Deprecated 2016-01-31) of $0 for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-13.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized · last filed 2014-03-13
- OMEROS CORP deferred revenue, revenue recognized (deprecated 2016-01-31) for fiscal 2013 was $0.00.
- OMEROS CORP deferred revenue, revenue recognized (deprecated 2016-01-31) for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- OMEROS CORP deferred revenue, revenue recognized (deprecated 2016-01-31) for fiscal 2011 was $230.00K.
| Period end | Deferred Revenue, Revenue Recognized (Deprecated 2016-01-31) 12 month |
|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-03-13 |
| 2012-12-31 | $0.00 10-K · filed 2014-03-13 |
| 2011-12-31 | $230.00K 10-K · filed 2014-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |